Mar 16, 2022 Press Release for Alnylam
Alnylam Issues 2021 Corporate Responsibility Report
Mar 16, 2022
–Report Features New Disclosures of Company’s Impact on Planet—Including Scope 1, 2, and Select Scope 3
– Aligns with the
“Since Alnylam’s inception, corporate responsibility has been a guiding principle for who we are and how we operate around the globe,” said
Key highlights from this report include:
-
Establishment of baseline measures of Alnylam’s environmental impact. In 2021,
Alnylam launched a comprehensive and ongoing process to quantify and mitigate the company’s greenhouse gas (GHG) emissions and waste management. As a result, the company can now assess and disclose its impact on the planet for the first time, including the disclosure of scope 1, 2, and select scope 3 GHG emissions, and align these disclosures with the GRI and SASB frameworks.
-
Strengthening of the structure and oversight of corporate responsibility at
Alnylam .Alnylam hired its first director of corporate responsibility and established a global steering committee, which oversees working groups dedicated to advancing the company’s five pillars of corporate responsibility: patients, science, employees, communities, and planet.
-
Expanded efforts addressing health inequities in local communities. Embedded in Alnylam’s culture is a commitment to tackle barriers to health and healthcare access for all. In 2021, the company launched Alnylam Challengers with a
$1 million investment in non-profit partner Acumen America. This community impact initiative advances bold, social enterprises that tackle health inequalities for underrepresented populations and people living in underserved communities.
- Enhancements to Alnylam’s Diversity, Equity, and Inclusion (DEI) plan. The company is assessing and enhancing DEI-related policies and actions in all aspects of its operations and interactions. DEI goals are framed around five key focus areas and includes an externally focused goal to increase diversity in our clinical trials processes.
To learn more about corporate responsibility at
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005045/en/
(Investors and Media)
617-682-4340
(Investors)
617-551-8276
Source:
For Media Inquiries, please contact:
Christine Lindenboom
SVP, Investor Relations & Corporate Communications media@alnylam.com 617-682-4340
For Investor Inquiries, please contact:
Josh Brodsky
VP, Investor Relations & Corporate Communications investors@alnylam.com 617-551-8276
MEDIA KIT
Essential assets and documents related to Alnylam